Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
Authors: Kashani Kianoush , Al-Khafaji Ali , Ardiles Thomas , Artigas Antonio , Bagshaw Sean M , Bell Max , Bihorac Azra , Birkhahn Robert , Cely Cynthia M , Chawla Lakhmir S , Davison Danielle L , Feldkamp Thorsten , Forni Lui G , Gong Michelle Ng , Gunnerson Kyle J , Haase Michael , Hackett James , Honore Patrick M , Hoste Eric AJ , Joannes-Boyau Olivier , Joannidis Michael , Kim Patrick , Koyner Jay L , Laskowitz Daniel T , Lissauer Matthew E , Marx Gernot , McCullough Peter A , Mullaney Scott , Ostermann Marlies , Rimmelé Thomas , Shapiro Nathan I , Shaw Andrew D , Shi Jing , Sprague Amy M , Vincent Jean-Louis , Vinsonneau Christophe , Wagner Ludwig , Walker Michael G , Wilkerson R Gentry , Zacharowski Kai , Kellum John A 
Published: February 2013

Introduction

Acute kidney injury (AKI) can evolve quickly and clinical measures of function often fail to detect AKI at a time when interventions are likely to provide benefit. Identifying early markers of kidney damage has been difficult due to the complex nature of human AKI, in which multiple etiologies exist. The objective of this study was to identify and validate novel biomarkers of AKI.

Methods

We performed two multicenter observational studies in critically ill patients at risk for AKI - discovery and validation. The top two markers from discovery were validated in a second study (Sapphire) and compared to a number of previously described biomarkers. In the discovery phase, we enrolled 522 adults in three distinct cohorts including patients with sepsis, shock, major surgery, and trauma and examined over 300 markers. In the Sapphire validation study, we enrolled 744 adult subjects with critical illness and without evidence of AKI at enrollment; the final analysis cohort was a heterogeneous sample of 728 critically ill patients. The primary endpoint was moderate to severe AKI (KDIGO stage 2 to 3) within 12 hours of sample collection.

Results

Moderate to severe AKI occurred in 14% of Sapphire subjects. The two top biomarkers from discovery were validated. Urine insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2), both inducers of G1 cell cycle arrest, a key mechanism implicated in AKI, together demonstrated an AUC of 0.80 (0.76 and 0.79 alone). Urine [TIMP-2]·[IGFBP7] was significantly superior to all previously described markers of AKI (P <0.002), none of which achieved an AUC >0.72. Furthermore, [TIMP-2]·[IGFBP7] significantly improved risk stratification when added to a nine-variable clinical model when analyzed using Cox proportional hazards model, generalized estimating equation, integrated discrimination improvement or net reclassification improvement. Finally, in sensitivity analyses [TIMP-2]·[IGFBP7] remained significant and superior to all other markers regardless of changes in reference creatinine method.

Conclusions

Two novel markers for AKI have been identified and validated in independent multicenter cohorts. Both markers are superior to existing markers, provide additional information over clinical variables and add mechanistic insight into AKI.

Trial registration

ClinicalTrials.gov number NCT01209169.